MA50391A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires - Google Patents

Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires

Info

Publication number
MA50391A
MA50391A MA050391A MA50391A MA50391A MA 50391 A MA50391 A MA 50391A MA 050391 A MA050391 A MA 050391A MA 50391 A MA50391 A MA 50391A MA 50391 A MA50391 A MA 50391A
Authority
MA
Morocco
Prior art keywords
treatment
pharmaceutical compositions
new compounds
inflammatory disorders
associated pharmaceutical
Prior art date
Application number
MA050391A
Other languages
English (en)
Other versions
MA50391B1 (fr
Inventor
David Amantini
Denis Maurice Annoot
Reginald Christophe Xavier Brys
Pieter Isabelle Roger Claes
Ghjuvanni Petru Diunisu Coti
René Alexandre Galien
Ramos Miriam López
Oscar Mammoliti
Sébastien Laurent Xavier Martina
Der Plas Steven Emiel Van
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA50391A publication Critical patent/MA50391A/fr
Publication of MA50391B1 publication Critical patent/MA50391B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA50391A 2017-10-20 2018-10-11 Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires MA50391B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2018/077677 WO2019076716A1 (fr) 2017-10-20 2018-10-11 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires

Publications (2)

Publication Number Publication Date
MA50391A true MA50391A (fr) 2021-04-21
MA50391B1 MA50391B1 (fr) 2023-11-30

Family

ID=60481889

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50391A MA50391B1 (fr) 2017-10-20 2018-10-11 Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires

Country Status (31)

Country Link
US (2) US11564923B2 (fr)
EP (2) EP4265254A3 (fr)
JP (2) JP7292271B2 (fr)
KR (1) KR102757425B1 (fr)
CN (2) CN117534670A (fr)
AR (1) AR113784A1 (fr)
AU (2) AU2018350592B2 (fr)
BR (1) BR112020007541A2 (fr)
CA (1) CA3079449A1 (fr)
CO (1) CO2020005200A2 (fr)
DK (1) DK3697784T5 (fr)
ES (1) ES2967432T3 (fr)
FI (1) FI3697784T5 (fr)
GB (1) GB201717260D0 (fr)
HR (1) HRP20231315T1 (fr)
HU (1) HUE063998T2 (fr)
IL (2) IL302615B2 (fr)
LT (1) LT3697784T (fr)
MA (1) MA50391B1 (fr)
MX (1) MX2020003863A (fr)
MY (1) MY205443A (fr)
PH (1) PH12020550230A1 (fr)
PL (1) PL3697784T3 (fr)
PT (1) PT3697784T (fr)
RS (1) RS64800B1 (fr)
SG (1) SG11202003516TA (fr)
SI (1) SI3697784T1 (fr)
SM (1) SMT202300377T1 (fr)
TW (2) TWI866258B (fr)
WO (1) WO2019076716A1 (fr)
ZA (1) ZA202002166B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
JP7592029B2 (ja) 2019-05-28 2024-11-29 マンカインド ファーマ リミテッド ヤヌスキナーゼ１の阻害のための新規化合物
TW202246232A (zh) 2021-02-19 2022-12-01 英商蘇多生物科學有限公司 Ｔｙｋ２抑制劑及其用途
TW202246233A (zh) 2021-02-19 2022-12-01 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
EP4370128A1 (fr) 2021-07-12 2024-05-22 Galapagos N.V. Traitement de maladies inflammatoires
AU2022412835A1 (en) 2021-12-16 2024-06-20 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023161327A1 (fr) * 2022-02-24 2023-08-31 Galapagos Nv Procédés de traitement de maladies inflammatoires et composé destiné à être utilisé dans ces procédés
WO2023161326A1 (fr) 2022-02-24 2023-08-31 Galapagos Nv Procédés de traitement de maladies inflammatoires et composé destiné à être utilisé dans ces procédés
JP2024082106A (ja) * 2022-12-07 2024-06-19 富士通株式会社 情報処理プログラム、情報処理方法および情報処理装置
PE20252285A1 (es) 2023-01-18 2025-09-18 Galapagos Nv Composiciones farmaceuticas para el tratamiento de trastornos inflamatorios
KR20250130699A (ko) 2023-01-19 2025-09-02 갈라파고스 엔.브이. 알레르기 질환, 염증 질환, 대사 질환, 자가염증 질환, 자가면역 질환, 및 증식성 질환의 치료에 유용한 이미다조[4,5-b]피리딘 유도체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017012647A1 (fr) 2015-07-20 2017-01-26 Galapagos Nv Nouveaux composés et compositions pharmaceutiques les comprenant pour le traitement de troubles inflammatoires
AR105400A1 (es) 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
AU2017345736B2 (en) * 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
CA3079449A1 (fr) 2019-04-25
IL302615A (en) 2023-07-01
PT3697784T (pt) 2024-01-09
RS64800B1 (sr) 2023-11-30
BR112020007541A2 (pt) 2020-09-24
EP4265254A2 (fr) 2023-10-25
EP3697784B9 (fr) 2023-12-27
IL273943B1 (en) 2023-06-01
LT3697784T (lt) 2023-10-25
AU2018350592B2 (en) 2022-12-22
TW201918483A (zh) 2019-05-16
MY205443A (en) 2024-10-22
JP7292271B2 (ja) 2023-06-16
IL273943A (en) 2020-05-31
KR20200074178A (ko) 2020-06-24
MX2020003863A (es) 2020-08-13
US20210169879A1 (en) 2021-06-10
AU2018350592A1 (en) 2020-06-04
TW202411229A (zh) 2024-03-16
WO2019076716A1 (fr) 2019-04-25
TWI805629B (zh) 2023-06-21
GB201717260D0 (en) 2017-12-06
EP4265254A3 (fr) 2024-03-13
FI3697784T5 (fi) 2024-01-12
HUE063998T2 (hu) 2024-02-28
AU2023201522B2 (en) 2024-11-28
KR102757425B1 (ko) 2025-01-20
CN117534670A (zh) 2024-02-09
TWI866258B (zh) 2024-12-11
MA50391B1 (fr) 2023-11-30
JP2020537672A (ja) 2020-12-24
US20230310433A1 (en) 2023-10-05
DK3697784T5 (da) 2024-01-15
IL302615B2 (en) 2024-10-01
SG11202003516TA (en) 2020-05-28
IL273943B2 (en) 2023-10-01
RU2020116376A (ru) 2021-11-22
AU2023201522A1 (en) 2023-04-13
CN111225916A (zh) 2020-06-02
US12472181B2 (en) 2025-11-18
JP2023113834A (ja) 2023-08-16
AR113784A1 (es) 2020-06-10
EP3697784A1 (fr) 2020-08-26
FI3697784T3 (fi) 2023-10-31
JP7654031B2 (ja) 2025-03-31
ES2967432T3 (es) 2024-04-30
HRP20231315T1 (hr) 2024-02-16
IL302615B1 (en) 2024-06-01
EP3697784B1 (fr) 2023-10-04
PH12020550230A1 (en) 2021-02-08
DK3697784T3 (da) 2023-10-30
RU2020116376A3 (fr) 2021-11-22
CN111225916B (zh) 2023-11-03
SI3697784T1 (sl) 2023-11-30
US11564923B2 (en) 2023-01-31
SMT202300377T1 (it) 2024-01-10
ZA202002166B (en) 2021-05-26
CO2020005200A2 (es) 2020-05-29
PL3697784T3 (pl) 2024-03-11

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
LU92577B1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
MA55497A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP3890747A4 (fr) Compositions pour le traitement de la fibrose et de l'inflammation
EP3841086A4 (fr) Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3774743C0 (fr) Composés de type promédicaments activés par akr1c3 et leur utilisation pour le traitement de troubles hyperprolifératifs
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3941462A4 (fr) Composés pharmaceutiques pour le traitement de troubles médiés par le complément
EP3661553A4 (fr) Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif